REG - Avacta Group PLC - Director/PDMR Shareholding

AvactaAnnouncement

29/09/2023 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc2159Oa&default-theme=true

RNS Number : 2159O  Avacta Group PLC  29 September 2023

29 September 2023

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Director/PDMR Shareholdings

 

 

Avacta Group plc (AIM: AVCT), a life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics,
announces it has granted a total of 2,500,000 options over ordinary shares of
10p each ("Ordinary Shares") to certain directors of the Company (the
"Options").

 

These Options were granted under the Company's Long term Incentive Plan,
Avacta Group plc Executive Share Option Scheme as set out below:

 

 Director        Position  Number of Options Granted  Exercise Price
 Alastair Smith  CEO       1,250,000                  10p
 Tony Gardiner   CFO       1,250,000                  10p

 

The vesting conditions are based on the share price performance of the Company
over the three year period up to 31 December 2025 relative to the performance
of the FTSE AIM All Share Index during the same period.

 

Following these awards, the total number of Options held by the directors were
as set out below:

 

 Director        Position  Number of Options held
 Alastair Smith  CEO       6,241,426
 Tony Gardiner   CFO       2,828,384

 

 

 

Dr Eliot Forster, Chairman of Avacta Group plc said:

"Following the completion of the 2020 LTIP award period and the significant
progress made within the Group during the year, I am pleased to confirm that
the Remuneration Committee has been able to conclude the changes to the equity
arrangements of Alastair and Tony. These arrangements continue to align the
interest of the Executive Directors with the longer-term share price
performance interests of our shareholders."

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                          Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                   www.avacta.com (http://www.avacta.com/)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                   Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William   www.stifel.com (http://www.stifel.com/)
 Palmer-Brown

 Peel Hunt (Joint Broker)

 James Steel / Chris Golden / Patrick Birkholm                             www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji                       avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 

 

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com/)

 

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, which is executing on an M&A led growth strategy to
create a full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two proprietary
platforms, Affimer(®) and pre|CISION(TM) underpin its cancer therapeutics
whilst the diagnostics division leverages the Affimer(®) platform to drive
competitive advantage in its markets.

 

The pre|CISION(TM) platform modifies chemotherapy to be activated only in the
tumour tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumours compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION(TM) programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

Affimer(®) is a novel biologic platform which has significant technical and
commercial advantages compared with antibodies and is used both to develop
advanced immunotherapies and to improve the performance of immunodiagnostics.

 

With a balanced business and capital allocation model: a high-value oncology
pipeline supported by a revenue generating, fast-growing diagnostics business,
Avacta seeks to create long-term shareholder value alongside patient benefit.

 

 

To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Alastair Smith
 2.                        Reason for the Notification
 a)                        Position/status                                              Chief Executive Officer
 b)                        Initial notification/Amendment                               Initial notification
 3.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Avacta Group Plc
 b)                        LEI                                                          2138009U3EG31OPMGH36
 4.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument

Options over Ordinary Shares
                           Identification code                                          GB00BYYW9G87
 b)                        Nature of the transaction

Grant of Options over Ordinary Shares

 c)                        Price(s) and volume(s)

                                                                                        LTIP

Exercise Price(s)  Volume(s)
                                                                                        10.00 pence        1,250,000
 d)                        Aggregated information:                                      Grant of 1,250,000 options over Ordinary Shares at an exercise price of 10p

                           ·      Aggregated volume

                           ·      Price
 e)                        Date of the transaction                                      28 September 2023
 f)                        Place of the transaction                                     Outside a trading venue

3.

Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

 Options over Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

 Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

LTIP

 Exercise Price(s)  Volume(s)
 10.00 pence        1,250,000

d)

Aggregated information:

·      Aggregated volume

·      Price

Grant of 1,250,000 options over Ordinary Shares at an exercise price of 10p

e)

Date of the transaction

28 September 2023

f)

Place of the transaction

Outside a trading venue

 

 

 1.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Tony Gardiner
 2.                        Reason for the Notification
 a)                        Position/status                                              Chief Financial Officer
 b)                        Initial notification/Amendment                               Initial notification
 3.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Avacta Group Plc
 b)                        LEI                                                          2138009U3EG31OPMGH36
 4.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument

Options over Ordinary Shares
                           Identification code                                          GB00BYYW9G87
 b)                        Nature of the transaction

Grant of Options over Ordinary Shares

 c)                        Price(s) and volume(s)

                                                                                        LTIP

Exercise Price(s)  Volume(s)
                                                                                        10.0 pence         1,250,000
 d)                        Aggregated information:                                      Grant of 1,250,000 options over Ordinary Shares at an exercise price of 10p

                           ·      Aggregated volume

                           ·      Price
 e)                        Date of the transaction                                      28 September 2023
 f)                        Place of the transaction                                     Outside a trading venue

3.

Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

 Options over Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

 Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

LTIP

 Exercise Price(s)  Volume(s)
 10.0 pence         1,250,000

d)

Aggregated information:

·      Aggregated volume

·      Price

Grant of 1,250,000 options over Ordinary Shares at an exercise price of 10p

e)

Date of the transaction

28 September 2023

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHNKCBBBBKDKCB